Data investigation

One Trial on Fertility

A systematic review searched five databases for everything on weight-lowering drugs and natural female fertility. Of the seven trials it turned up, six tested orlistat and exactly one tested a GLP-1.

By Nora Bissett · Pricing Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed
6 min read·1 citation

People are taking these drugs hoping to conceive, and unplanned pregnancies on them are discussed everywhere. A systematic review searched five databases for everything published on weight-lowering drugs and natural female fertility, screened 2,731 records, and found seven trials, six of which studied orlistat.[1] Exactly one assessed a GLP-1.

What the search returned

The seven clinical trials, six of them randomized, covered 575 women in total. Individual studies enrolled between 40 and 120 participants, aged on average between 25.9 and 29.7. The outcomes sought were ovulation, conception, pregnancy and live birth.

The entire published evidence base, as the review found it.[1]
ComparisonFinding
Orlistat vs lifestyle modification (4 trials)Higher ovulation rate with orlistat
Orlistat vs metformin, ovulation (meta-analysis)No significant difference — RR 0.78 (95% CI 0.41–1.49), p = 0.45
Orlistat vs lifestyle, pregnancy (1 trial)23.3% vs 6.7%, p = 0.044
Semaglutide + metformin vs metformin (1 trial)Pregnancy 35% vs 15%, p < 0.05
Live birthsNot adequately assessed by any of them

Orlistat is a drug that blocks fat absorption in the gut. It is barely prescribed now, and it is what six-sevenths of this literature is about. That is the practical meaning of the review: the evidence on weight-lowering drugs and fertility was mostly assembled before the drugs people now take existed.

The one GLP-1 result

A single trial found that adding semaglutide to metformin raised the pregnancy rate from 15% to 35%. More than doubling a pregnancy rate sounds like a large finding, but in a study of this size it is a small number of pregnancies.

The semaglutide trial enrolled 80 women.[1] Split evenly between the two arms, 35% against 15% is roughly fourteen pregnancies against six. A difference of that magnitude in numbers that small is the kind of result that shrinks or vanishes when a bigger study is run.

The outcome is also pregnancy, not a baby. The review says plainly that future studies need to evaluate live birth rates in adequately powered studies, which is an acknowledgment that the outcome people want has not been measured.

Nobody has published whether these drugs help anyone have a baby.

The tension nobody resolves

Every label for these drugs directs stopping before a planned pregnancy. So the situation this evidence describes is one where a drug may help someone conceive, and is contraindicated in the pregnancy it helps produce. Nobody has resolved that contradiction. It is a difficult position, and it belongs in front of anyone taking one of these drugs while hoping to become pregnant.

It also matters that fertility can return before anyone plans for it. Weight loss can restore ovulation in people who were not ovulating; that is the mechanism most of this literature is built on. It means conception can happen while someone still assumes it cannot. The label intervals, what 36 studies say about exposure around conception, and the first measurement of whether semaglutide reaches breast milk are all in pregnancy and trying to conceive.

For the specific case of polycystic ovary syndrome, where the fertility question has its own literature, see GLP-1s for PCOS.

What can be said

  • Weight loss improves fertility in people whose fertility is impaired by weight. That is long established and is not in question.
  • Whether these particular drugs do it better than other routes to the same weight loss is unstudied. One trial is not an evidence base.
  • Nobody has measured live births. Pregnancy rate is a step short of the outcome.
  • Contraception matters more than people expect while taking these drugs, precisely because fertility can return unannounced.

None of this argues against treatment. It argues for treating a widely repeated story as unproven, and for having the conversation with a clinician before rather than after.

Frequently Asked Questions

A systematic review of everything published on weight-lowering drugs and natural female fertility found seven trials, six of them on orlistat. One trial of semaglutide added to metformin reported a pregnancy rate of 35% against 15%. That single study is the entire published evidence base.
It is a large relative difference in a very small study. The semaglutide trial enrolled 80 women, so the finding rests on a handful of pregnancies. Differences of that size in numbers that small frequently shrink when larger studies are run.
Unknown. The review states that live birth rates have not been adequately assessed and calls for adequately powered studies. Pregnancy rate is one step short of the outcome people are seeking.
Every label directs discontinuation before a planned pregnancy. That creates a real tension with the possibility that the drug improves conception, and it is a conversation to have with a clinician in advance.
Weight loss can restore ovulation in someone who was not ovulating, so fertility returns before anyone plans for it. That is the mechanism most of this literature rests on, and it is why contraception matters more than people expect.

References

  1. 1.Alnaimi SJ, Alsugeir DM, Wei L, et al. Weight-Lowering Drugs and Natural Female Fertility—A Systematic Review and Meta-Analysis Clinical Obesity. 2026. PMID: 42307450.

Kisspeptin: What the Human Studies Show, and What They Don't

Kisspeptin, the hypothalamic hormone that drives GnRH and LH, works in hospital studies as a hypogonadism test and an IVF trigger. It has no weight-loss trials, no FDA approval, and kisspeptin-10 is in FDA's Category 2 for safety risks.

11 min read

How Long Do Zepbound, Wegovy and Other GLP-1s Stay in Your System?

Half-lives and washout times for tirzepatide (Zepbound, Mounjaro), semaglutide (Wegovy, Ozempic), liraglutide, dulaglutide, orforglipron and investigational retatrutide, from FDA labels and trial data, with what the labels say about stopping before pregnancy or surgery.

7 min read

A Composite Is Only Its Components

A reanalysis found tirzepatide getting far more patients to three or more treatment targets. The comparator was semaglutide at 1 mg, and the gap was carried by two of the four targets.

7 min read

The Drugs Nobody Writes About

A pharmacovigilance study found muscle atrophy reported disproportionately with semaglutide and tirzepatide. The same table shows two older drugs of the same class reported significantly less often than average.

6 min read

A Biomarker Is Not an Outcome

Sixteen cardiovascular risk markers were measured in SURMOUNT-1 at 72 weeks, and most improved substantially. Cardiology has learned twice, expensively, why that is not the same as preventing events.

8 min read

The Mental Health Score That Did Not Move

In the head-to-head trial, physical quality-of-life scores improved clearly over 72 weeks. The Mental Component Summary did not significantly improve in either arm, a result the paper's own conclusion omits.

6 min read